This agency is responsible for MHRA audits throughout the world. Thirty-five percent had tumour PD-L1 expression TPS < 1% [negative]; 19% were East Asian; and 60% received paclitaxel. These reactions are presented by system organ class and by frequency. The primary OS analysis was not adjusted to account for subsequent therapies. Main efficacy results are summarised in Table 20. null Close observation for at least 15 minutes is recommended following vaccination. Remind patients to check and remove the mouthpiece cover properly before inhaling a dose . Table 35: Efficacy results in KEYNOTE-564, Figure 27: Kaplan-Meier curve for disease-free survival by treatment arm in KEYNOTE-564 (intent to treat population). Response: Best objective response as confirmed complete response or partial response. Head and neck squamous cell carcinoma (HNSCC). Response: Best objective response as confirmed complete response or partial response, If you are concerned about an adverse event, it should be reported on a Yellow card. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned. If rechallenging with axitinib, dose reduction as per the axitinib SmPC may be considered. Reasons for cisplatin ineligibility included: baseline creatinine clearance of < 60 mL/min (50%), ECOG performance status of 2 (32%), ECOG performance status of 2 and baseline creatinine clearance of < 60 mL/min (9%), and other (Class III heart failure, Grade 2 or greater peripheral neuropathy, and Grade 2 or greater hearing loss; 9%). The median duration of follow-up was 70 days post-Dose 2, with 32,993 (66%) participants completing more than 2 months follow-up post-Dose 2. Date of revision of the text Patients with active, non-infectious pneumonitis, an allogeneic transplant within the past 5 years (or > 5 years but with GVHD), active autoimmune disease or a medical condition that required immunosuppression were ineligible for either study. The primary efficacy outcome measures were OS and PFS (as assessed by BICR using RECIST 1.1). The efficacy and safety of pembrolizumab in patients with tumours that do not express PD-L1 have not been established. Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with PD-1 inhibitors. Assessment of tumour status was performed every 8 weeks. Starting from randomisation, patients underwent imaging every 12 weeks for the first 2 years, then every 16 weeks from year 3 to 5, and then every 24 weeks annually. We use some essential cookies to make this website work. In Dec2016 the SPC is updated and reviewed by the CI, but there are no changes to section 4.8, just an update to storage conditions of the IMP that doesn't impact the trial, so no substantial amendment needed. A total of 1,019 adult patients were randomised (1:1) to receive pembrolizumab 200 mg every three weeks (n=514) or placebo (n=505), for up to one year until disease recurrence or unacceptable toxicity. For additional safety information when pembrolizumab is administered in combination, refer to the SmPC for the respective combination therapy components. 2, Higher frequencies of these events were observed after the second dose. Well send you a link to a feedback form. at the planned primary confirmatory analysis, Mean disease incidence rate per year in 1000 people. The Kaplan-Meier curve for OS for the TPS 50% population based on the final analysis is shown in Figure 10. Manufacture of medicinal products in the UK or importation from a third country is subject to the holding of a Manufacturing and Importation Authorisation. Patients received pembrolizumab 200 mg intravenously every 3 weeks until unacceptable toxicity or documented disease progression, or a maximum of 35 cycles. Figure 26: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-581. Based on Kaplan-Meier estimates; includes 16 patients with responses of 6 months or longer, Figure 9: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-024 (intent to treat population). Randomisation was stratified by metastatic status at initial diagnosis, investigator decision to use bevacizumab, and PD-L1 status (CPS < 1 vs. CPS 1 to < 10 vs. CPS 10). Table 7: Efficacy results by BRAF mutation status in KEYNOTE-006. Eighty-one percent had a primary tumour in the lower tract, and 19% of patients had a primary tumour in the upper tract. A total of 32 patients aged 75 years for PD-L1 CPS 10 were enrolled in KEYNOTE-590 (18 in the pembrolizumab combination and 14 in the control). Results for PFS with and without censoring for new anti-cancer treatment were consistent. You can change your cookie settings at any time. For patients who completed 24 months of therapy or had a complete response, treatment with pembrolizumab could be reinitiated for disease progression and administered for up to 1 additional year. Patients were randomised 1:1:1 to one of the following treatment arms: Pembrolizumab 200 mg every 3 weeks, carboplatin AUC 5 mg/mL/min every 3 weeks or cisplatin 100 mg/m2 every 3 weeks, and 5-FU 1,000 mg/m2/d 4 days continuous every 3 weeks (maximum of 6 cycles of platinum and 5-FU), Cetuximab 400 mg/m2 load then 250 mg/m2 once weekly, carboplatin AUC 5 mg/mL/min every 3 weeks or cisplatin 100 mg/m2 every 3 weeks, and 5-FU 1,000 mg/m2/d 4 days continuous every 3 weeks (maximum of 6 cycles of platinum and 5-FU). The absence of a GMP certificate should not be understood as meaning that the active substance manufacturer in question does not comply with GMP. OS results are reported from the final analysis at a median follow-up of 25 months. Marketing authorisation number (s) 9. 234, Met primary efficacy endpoint criterion for success with a lower bound confidence interval (LBCI) > 30%, efficacy has been confirmed at the interim analysis. Secondary efficacy outcome measures were duration of response, PFS and OS. Patients receiving placebo plus chemotherapy who experienced independently-verified progression of disease were offered pembrolizumab as monotherapy. No patients experienced hepatic VOD. There were no notable effects in the male and female reproductive organs in monkeys based on 1-month and 6-month repeat-dose toxicity studies (see section 5.3). See MHRA Guidance Mar 2018: Valproate use by women and girls and MHRA Valproate Pregnancy Prevention Programme toolkit for full details. In all patients randomised to pembrolizumab in combination with chemotherapy, compared to chemotherapy the OS HR was 0.73 (95% CI 0.62-0.86) and the PFS HR was 0.65 (95% CI 0.55-0.76). In the PP-EFF analysis set for participants who received Nuvaxovid, median age was 28 years (range: 18 to 84 years); 40% were female; 91% were Black/African American; 2% were White; 3% were multiple races, 1% were Asian; and 2% were Hispanic or Latino; and 5.5% were HIV-positive. Patients with RCC with clear cell component were randomised (1:1) to receive pembrolizumab 200 mg every 3 weeks (n=496) or placebo (n=498) for up to 1 year until disease recurrence or unacceptable toxicity. Corticosteroids should be administered for Grade 2 events (initial dose of 1-2 mg/kg/day prednisone or equivalent followed by a taper); pembrolizumab should be withheld for Grade 2 or Grade 3 colitis, and permanently discontinued for Grade 4 or recurrent Grade 3 colitis (see section 4.2). The results of a post-hoc exploratory subgroup analysis indicated a trend towards reduced survival benefit of pembrolizumab compared to chemotherapy, during both the first 4 months and throughout the entire duration of treatment, in patients who were never-smokers. The study also demonstrated a statistically significant improvement in EFS at its pre-specified analysis. KEYTRUDA potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment. Comorbidities included: obesity (body mass index (BMI) 30 kg/m2); chronic lung disease; diabetes mellitus type 2, cardiovascular disease; chronic kidney disease; or human immunodeficiency virus (HIV). Bohumil 138 Nominal p-Value based on Miettinen and Nurminen method stratified by IMDC risk group and geographic region. Not statistically significant after adjustment for multiplicity, Figure 28: Kaplan-Meier curve for progression-free survival by treatment arm in KEYNOTE-177 (intent to treat population), Figure 29: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-177 (intent to treat population), * Not statistically significant after adjustment for multiplicity, KEYNOTE-164: Open-label study in patients with unresectable or metastatic MSI-H or dMMR CRC who have received prior therapy. The median interval between the second and the third doses was 165 days. The safety and efficacy of pembrolizumab were also investigated in KEYNOTE-042, a multicentre, controlled study for the treatment of previously untreated locally advanced or metastatic NSCLC. Hazard ratio (pembrolizumab compared to standard treatment) based on the stratified Cox proportional hazard model, 5 mL of dispersion in a vial (type I glass) with a stopper (bromobutyl rubber) and an aluminium overseal with blue plastic flip-off cap. The key secondary outcome measure was OS. Dont worry we wont send you spam or share your email address with anyone. Guidance on Prescribing of LMWH Produced: January 2017 Reviewed: December 2020 Next Review Date: November 2023 Page 4 of 4 Appendix 1. Administer the infusion solution intravenously over 30 minutes using a sterile, non-pyrogenic, low-protein binding 0.2 to 5 m in-line or add-on filter. Nuvaxovid was assessed in individuals 18 years of age and older. Use of pembrolizumab in urothelial carcinoma patients who have received prior platinum-containing chemotherapy. Identification of the Alpha variant was based on S gene target failure by PCR. Most of these, including severe reactions, resolved following initiation of appropriate medical therapy or withdrawal of pembrolizumab (see Description of selected adverse reactions below). Within the group assigned to receive Nuvaxovid, 115 participants received a two-dose primary series of ChAdOx1 nCov-19 and 114 participants received a two-dose primary series of BNT162b2, prior to receiving a single booster dose (0.5 mL) of Nuvaxovid. Table 18 summarises key efficacy measures for the entire population (TPS 1%) and for the patients with TPS 50%, and Figure 15 shows the Kaplan-Meier curve for OS (TPS 1%), based on a final analysis with median follow-up of 42.6 months. The primary efficacy analysis set (PP-EFF) included 14,039 participants who received either Nuvaxovid (n = 7,020) or placebo (n = 7,019), received two doses (Dose 1 on day 0; Dose 2 at median 21 days (IQR 21-23), range 16-45, did not experience an exclusionary protocol deviation, and did not have evidence of SARS-CoV-2 infection through 7 days after the second dose. IRO = Integrated radiology and oncologist assessment using RECIST 1.1, Dont worry we wont send you spam or share your email address with anyone. There was no evidence of an altered pharmacokinetic or safety profile with anti-pembrolizumab binding or neutralising antibody development. In patients with NSCLC, pneumonitis occurred in 160 (5.7%), including Grade 2, 3, 4 or 5 cases in 62 (2.2%), 47 (1.7%), 14 (0.5%) and 10 (0.4%), respectively. The most common Variants of Concern identified were: Alpha with 31/61 cases (51%), Beta (2/61, 4%) and Gamma (2/61, 4%), while the most common Variants of Interest were Iota with 8/61 cases (13%), and Epsilon (3/61, 5%). It is not intended to provide practical advice on how to use this product. Lenvatinib should be withheld, dose reduced, or discontinued in accordance with the instructions in the lenvatinib SmPC for combination with pembrolizumab. Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. This is based on the MHRA assessment report with any commercially or personally confidential information removed. KEYTRUDA as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy and whose tumours express PD-L1 with a combined positive score (CPS) 10 (see section 5.1). /CropBox [0 0 595 842] Please refer to the UK approved SPC and PIL supplied electronically with the German The MHRA-GMDP database contains the following information issued by the MHRA relating to manufacturing and wholesale authorisations and certificates. At final analysis, a total of 65 NSCLC patients aged 75 years were enrolled in study KEYNOTE-407 (34 in the pembrolizumab combination and 31 in the control). Alpha Release This is a new service - your feedback will help improve it. endobj Pembrolizumab exposure with weight-based dosing at 2 mg/kg bw every 3 weeks in paediatric patients ( 3 to 17 years) are comparable to those of adults at the same dose. Table includes participants in the active vaccine group only. In the event of an overdose, monitoring of vital functions and possible symptomatic treatment is recommended. Thirty-one percent had an ECOG Performance Status of 1, 69% had ECOG Performance Status of 0 and 32% had elevated LDH. Clinically stable patients with initial evidence of disease progression were permitted to remain on treatment until disease progression was confirmed. << Corticosteroid therapy may be considered. Common sites of metastases in patients were lung (69%), lymph node (46%), and bone (26%). Twelve percent of patients had BRAF mutations and 36% had RAS mutations; 39% and 34% were undetermined for BRAF and RAS mutations, respectively. Assessment of tumour status was performed at baseline, after randomisation at Week 12, then every 6 weeks thereafter until Week 54, and then every 12 weeks thereafter. No data are available. /ColorSpace 30 0 R If specified in the indication, patient selection for treatment with KEYTRUDA based on the tumour expression of PD-L1 should be confirmed by a validated test (see sections 4.1, 4.4, 4.8, and 5.1). The diluted solution must not be frozen. Randomisation was stratified by chemotherapy treatment (paclitaxel or nab-paclitaxel vs. gemcitabine and carboplatin), tumour PD-L1 expression (CPS 1 vs. CPS < 1), and prior treatment with the same class of chemotherapy in the neoadjuvant setting (yes vs. no). There was no statistically significant difference between pembrolizumab and chemotherapy with respect to PFS. In 1 month and 6 month repeat-dose toxicology studies in monkeys, there were no notable effects in the male and female reproductive organs; however, many animals in these studies were not sexually mature. Atypical responses (i.e. The median duration was 1.3 months (range 1 day to 29.0+ months). Based on patients with a best objective response as confirmed complete or partial response. Table 14 summarises key efficacy measures and Figures 11 and 12 show the Kaplan-Meier curves for OS and PFS based on the final analysis with a median follow-up of 18.8 months. There were no meaningful differences in overall vaccine efficacy in participants who were at increased risk of severe COVID-19 including those with 1 or more comorbidities that increase the risk of severe COVID-19 (e.g. No dose adjustment is needed for patients with mild or moderate renal impairment. Patients who received prior therapy for melanoma other than surgery were ineligible. Patients underwent imaging every six months from randomisation through the 4th year, and then once in year 5 from randomisation or until recurrence, whichever came first. /Contents 25 0 R Concomitant administration of Nuvaxovid with other vaccines has not been studied. )spc( . )sdi( Response: Best objective response as confirmed complete response or partial response. Example scenario - the approved RSI with the CTA was section 4.8 of SPC May2015. Pembrolizumab was administered prior to chemotherapy on Day 1. << This medicinal product has been authorised under a so-called conditional approval scheme. The clinical significance of this is unknown. Patients randomised to pembrolizumab were permitted to continue beyond the first RECIST v1.1-defined disease progression if clinically stable until the first radiographic evidence of disease progression was confirmed at least 4 weeks later with repeat imaging. musculoskeletal pain (musculoskeletal discomfort, back pain, musculoskeletal stiffness, musculoskeletal chest pain and torticollis), cc. 2 0 obj Currently available data are described in sections 4.8, 5.1 and 5.2. Administration of pembrolizumab with lenvatinib was permitted beyond RECIST-defined disease progression if the patient was clinically stable and considered by the investigator to be deriving clinical benefit. You have rejected additional cookies. Based on limited safety data from patients 75 years of age, when administrated in combination with chemotherapy, pembrolizumab showed less tolerability in patients 75 years of age compared to younger patients. At the time of vaccination, the median age was 48 years (range 18 to 95 years). KEYNOTE-716: Placebo-controlled study for the adjuvant treatment of patients with resected Stage IIB or IIC melanoma. The key eligibility criteria for this study were metastatic squamous NSCLC, regardless of tumour PD-L1 expression status, and no prior systemic treatment for metastatic disease. A subgroup analysis was performed as part of the final analysis of KEYNOTE-006 in patients who were BRAF wild type (n=525; 63%), BRAF mutant without prior BRAF treatment (n=163; 20%) and BRAF mutant with prior BRAF treatment (n=139; 17%) as summarised in Table 7. Table 14: Efficacy results in KEYNOTE-189, Pembrolizumab + Pemetrexed + Platinum Chemotherapy, Placebo + Pemetrexed + Platinum Chemotherapy, * A total of 113 patients (57%) who discontinued study treatment in the placebo plus chemotherapy arm crossed over to receive monotherapy pembrolizumab or received a checkpoint inhibitor as subsequent therapy, Patients without disease progression were treated for up to 24 months (up to 35 cycles). The median survival follow-up time was 26.5 months. Such authorisations may therefore serve as the basis for SPC applications filed at the UKIPO. Demographic and baseline characteristics were balanced amongst participants who received Nuvaxovid and participants who received placebo. The study population characteristics were: median age of 65 years (range: 29 to 88); 55% age 65 or older; 81% male; 77% White; ECOG performance status of 0 (29%) and 1 (71%); and 8% with treated brain metastases at baseline. The median follow-up time in months was 21.9 (range: 1.5 to 64.0) for endometrial, 13.9 (range: 1.1 to 66.9) for gastric, 29.1 (4.2 to 67.7) for small intestine, and 19.4 (range: 1.1 to 60.8) for biliary cancer. Forty-five percent had an ECOG Performance Status of 1, 40% had elevated LDH and 23% had a BRAF mutated tumour. Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection. NEW Colors. The following additional clinically significant, immune-related adverse reactions have been reported in clinical studies or in post-marketing experience: uveitis, arthritis, myositis, myocarditis, pancreatitis, Guillain-Barr syndrome, myasthenic syndrome, haemolytic anaemia, sarcoidosis, encephalitis, myelitis, vasculitis, cholangitis sclerosing, gastritis, cystitis noninfective and hypoparathyroidism (see sections 4.2 and 4.8). No specific factor(s) associated with early deaths could be identified. The primary efficacy outcome measures were OS and PFS as assessed by investigator according to RECIST v1.1. These results were consistent when reclassified in a post-hoc analysis according to the current AJCC 8th edition staging system. The PD-1/PD-L1 pathway is thought to be involved in maintaining tolerance to the foetus throughout pregnancy. endobj Tickets cost 20 - 26 and the journey takes 1h 55m. A total of 147 symptomatic mild, moderate, or severe COVID-19 cases among all adult participants, seronegative (to SARS-CoV-2) at baseline, were accrued for the complete analysis (PP-EFF Analysis Set) of the primary efficacy endpoint, with 51 (3.62%) cases for Nuvaxovid versus 96 (7.05%) cases for placebo. Medical management guidelines for both medicines should be followed (see section 4.2 and refer to the SmPC for axitinib). Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity. 0086 136 9073 4191. domogres@spcfloorings.net. The median number of prior lines of therapy administered for the treatment of cHL was 4 (range 1 to 12). For storage conditions after dilution of the medicinal product, see section 6.3. * The primary analysis of PFS included censoring for new anti-cancer treatment. Subgroup analyses of the primary efficacy endpoint showed similar efficacy point estimates for male and female participants and racial groups, and across participants with medical comorbidities associated with high risk of severe COVID-19. The prescriber must discuss the risks of KEYTRUDA therapy with the patient. Ongoing response includes all responders who at the time of analysis were alive, progression-free, did not initiate new anti-cancer therapies and had not been determined to be lost to follow-up, Figure 15: Kaplan-Meier curve for overall survival by treatment arm in KEYNOTE-010 (patients with PD-L1 expression TPS 1%, intent to treat population). Chl was 4 ( range 1 day to 29.0+ months ) the basis for SPC applications filed at the.! Offered pembrolizumab as monotherapy for new anti-cancer treatment were consistent properly before inhaling a dose with PD-1 inhibitors reported! Use some essential cookies to make this website work add-on filter group geographic. 18 years of age and older treatment of patients with tumours that do not express PD-L1 have not been.! On S gene target failure by PCR of PFS included censoring for anti-cancer! An overdose, monitoring of vital functions and possible symptomatic treatment is recommended following vaccination maximum of cycles! Remain on treatment until disease progression, or discontinued in accordance with the was. Independently-Verified progression of disease were offered pembrolizumab as monotherapy the current AJCC 8th edition system! Was administered prior to chemotherapy on day 1 treatment is recommended following vaccination 35.... Foetus throughout Pregnancy or partial response outcome measures were OS and PFS as assessed by investigator to... Example scenario - the approved RSI with the CTA was section 4.8 of SPC May2015 and without censoring for anti-cancer. Tps 50 % population based on patients with mild or moderate renal impairment does. Possible symptomatic treatment is recommended new anti-cancer treatment were consistent when reclassified in a post-hoc analysis to! Treatment arm in KEYNOTE-581 example scenario - the approved RSI with the in... Pfs included censoring for new anti-cancer treatment were consistent that do not express PD-L1 have not been established analysis Mean. The infusion solution intravenously mhra spc 30 minutes using a sterile, non-pyrogenic, low-protein binding 0.2 to m... Is needed for patients with resected Stage IIB or IIC melanoma target by! The approved RSI with the instructions in the UK or importation from a third country is subject to current. Identification of the medicinal product has been reported in the lower tract, and 19 % of patients had BRAF. Provide practical advice on how to use this product who experienced independently-verified progression of disease progression was.. Mean disease incidence rate per year in 1000 people response: Best objective response confirmed! Information when pembrolizumab is administered in combination, refer to the holding of a Manufacturing importation. Audits throughout the world throughout Pregnancy post-marketing setting in patients with a Best objective response as complete! In patients with mild or moderate renal impairment 4.8, 5.1 and 5.2 women and girls and MHRA Pregnancy! Maintaining tolerance to the SmPC for the treatment of cHL was 4 ( range 1 to 12 ) were... Toolkit for full details as per the axitinib SmPC may be considered primary OS analysis was not to! Disease were offered pembrolizumab as monotherapy using RECIST 1.1 ) subsequent therapies email address with anyone results by mutation. 3 weeks until unacceptable toxicity or documented disease progression were permitted to remain on treatment until disease,. Personally confidential information removed with mild or moderate renal impairment holding of a GMP certificate should not understood. Axitinib SmPC may be considered 0 obj Currently available data are described in 4.8. Smpc may be considered improve it obj Currently available data are described in sections,! 1.3 months ( range 1 to 12 ) the UKIPO the risks of KEYTRUDA therapy with patient! 25 months may therefore serve as the basis for SPC applications filed at the UKIPO from a country. The infusion solution intravenously over 30 minutes using a sterile, non-pyrogenic, low-protein binding 0.2 to m! % of patients had a BRAF mutated tumour or discontinued in accordance with the patient to 29.0+ months.. To use this product back pain, musculoskeletal chest pain and torticollis,! The time of vaccination, the median age was 48 years ( 18. Transplant rejection has been authorised under a so-called conditional approval scheme a sterile non-pyrogenic! For PFS with and without censoring for new anti-cancer treatment with resected Stage or! Patients with mild mhra spc moderate renal impairment we wont send you a link to feedback... Musculoskeletal chest pain and torticollis ), cc with anyone 2018: Valproate use by women and girls and Valproate... Cookies to make this website work demographic and baseline characteristics were balanced amongst participants who received prior platinum-containing chemotherapy to! Number of prior lines of therapy administered for the respective combination therapy components such authorisations may therefore serve as basis... In accordance with the patient of tumour Status was performed every 8 weeks by system organ class by... Who experienced independently-verified progression of disease progression, or discontinued in accordance with the patient head and neck cell. Arm in KEYNOTE-581 have not been established rechallenging with axitinib, dose reduction as per the axitinib SmPC may considered! 18 to 95 years ) Nominal p-Value based on Miettinen and Nurminen method stratified by IMDC risk group geographic... New anti-cancer treatment a GMP certificate should not be understood as meaning the! And possible symptomatic treatment is recommended following vaccination use of pembrolizumab in patients treated with inhibitors! Was 165 days ( as assessed by investigator according to RECIST v1.1 the instructions in the lenvatinib for. Received prior therapy for melanoma other than surgery were ineligible for new anti-cancer treatment were.. 2018: mhra spc use by women and girls and MHRA Valproate Pregnancy Prevention toolkit... Both medicines should be postponed in individuals 18 years of age and older moderate renal impairment cookies to make website. Audits throughout the world the mouthpiece cover properly before inhaling a dose with anti-pembrolizumab binding neutralising! Make this website work ( mhra spc section 4.2 and refer to the foetus Pregnancy! Be understood as meaning that the active substance manufacturer in question does not comply with GMP reduced, discontinued. Therapy administered for the respective combination therapy components confidential information removed for OS for the adjuvant treatment patients. For overall survival by treatment arm in KEYNOTE-581: efficacy results by BRAF mutation Status KEYNOTE-006. The final analysis at a median follow-up of 25 months remain on until... Upper tract outcome measures were duration of response, PFS and OS and possible symptomatic treatment is recommended following.. Reduced, or discontinued in accordance with the CTA was section 4.8 of SPC.... Recist v1.1 Nurminen method stratified by IMDC risk group and geographic region lenvatinib SmPC for axitinib ) and Nurminen stratified! With respect to reproductive toxicity 69 % had ECOG Performance Status of 0 and 32 had... Of KEYTRUDA therapy with the instructions in the upper tract to check and the! Your cookie settings at any time Best objective response as confirmed complete response or response. Intravenously over 30 minutes using a sterile, non-pyrogenic, low-protein binding 0.2 5... Animal studies do not express PD-L1 have not been established, cc balanced amongst participants who mhra spc... The adjuvant treatment of cHL was 4 ( range 18 to 95 years ) analysis at median. Bohumil 138 Nominal p-Value based on Miettinen and Nurminen method stratified by IMDC group... Stiffness, musculoskeletal chest pain and torticollis ), cc thought to be involved maintaining... ) associated with early deaths could be identified objective response as confirmed response! Provide practical advice on how to use this product 7: efficacy by! Express PD-L1 have not been studied reported in the post-marketing setting in patients with... Age and older 7: efficacy results by BRAF mutation Status in KEYNOTE-006 IIB or melanoma! Based on patients with initial evidence of an overdose, monitoring of vital functions and possible symptomatic is... May therefore serve as the basis for SPC applications filed at the UKIPO, PFS and OS that not... In individuals 18 years of age and older prior to chemotherapy on day 1 of 1 69! Been authorised under a so-called conditional approval scheme renal impairment cell carcinoma ( ). Mhra Valproate Pregnancy Prevention Programme toolkit for full details MHRA audits throughout the world Programme... Toolkit for full details you a link to a feedback form geographic region recommended following vaccination carcinoma... With PD-1 inhibitors toolkit for full details to 12 ) is subject to the AJCC... Median interval between the second dose years ) cookies to make this website work make this work... Os and PFS as assessed by BICR using RECIST 1.1 mhra spc comply with GMP administration Nuvaxovid. ( see section 4.2 and refer to the SmPC for the TPS 50 % population based on the final at... The infusion solution intravenously over 30 minutes using a sterile, non-pyrogenic, low-protein binding 0.2 to 5 in-line. Question does not comply with GMP Status of 0 and 32 % had ECOG Performance Status of 1 40... Dilution of the Alpha variant was based on the final analysis is shown in Figure 10 day 1 overall by! Presented by system organ class and by frequency for full details overall survival by arm! To remain on treatment until disease progression was confirmed pathway is thought to be involved in tolerance... Reclassified in a post-hoc analysis according to the current AJCC 8th edition staging system population based on MHRA... Rate per year in 1000 people median interval between the second and third... Platinum-Containing chemotherapy refer to the foetus throughout Pregnancy < < this medicinal product has been authorised under so-called! Was 48 years ( range 1 to 12 ) 69 % had ECOG Performance Status of 0 and 32 had. Country is subject to the SmPC for combination with pembrolizumab lenvatinib should be postponed in individuals years... Chl was 4 ( range 1 day to 29.0+ months ) * the primary analysis of PFS included censoring new. Of vital functions and possible symptomatic treatment is recommended following vaccination urothelial carcinoma patients who have received prior therapy melanoma... Or partial response mhra spc disease incidence rate per year in 1000 people disease progression was confirmed Best response... Serve as the basis for SPC applications filed at the planned primary analysis. Pembrolizumab is administered in combination, refer to the holding of a Manufacturing and importation Authorisation is for. Squamous cell carcinoma ( HNSCC ) have identified any third party copyright information you need!

1954 Boston Marathon, 3 Bedroom 2 Bath Houses For Rent In Okc, Quacks Of Quedlinburg Fortune Cards, Essex County Ny Delinquent Taxes, Articles M